Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors
The Journal of Korean Diabetes · 30.06.2021 · 22 (2) · 113-125
DOI: 10.4093/jkd.2021.22.2.113 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Korean Diabetes, erschienen am 30.06.2021. Verfasst von Dong Hyeok Cho. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Sodium glucose cotransporter-2 inhibitors (SGLT2i) block SGLT2 in the renal proximal tubule and increase the excretion of glucose into the urine, thereby decreasing serum glucose concentrations.These glucose-lowering effects are independent of insulin action.SGLT2i has been demonstrated to reduce cardiovascular complications and hospitalization for heart failure.SGLT2i has also shown remarkable inhibition effects on the progression of renal complications, decreasing serum creatinine, reducing albuminuria, and decreasing death from renal disease.These cardiorenal protective effects appear to be independent of glycemic control efficacy, and in view of these results, SGLT2i is recommended in type 2 diabetes patients at high risk of cardiovascular or renal disease.This review aims to provide an update on the mechanisms, efficacy, cardiorenal protective effects, and adverse effects of SGLT2i.
Zitieren
APA
Cho, D. H. (2021). Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors. The Journal of Korean Diabetes, 22(2), 113-125. https://doi.org/10.4093/jkd.2021.22.2.113
Vancouver
Cho DH. Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors. The Journal of Korean Diabetes. 2021;22(2):113-125. doi:10.4093/jkd.2021.22.2.113
BibTeX
@article{Cho2021,
author = {Cho, Dong Hyeok},
title = {Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors},
journal = {The Journal of Korean Diabetes},
year = {2021},
volume = {22},
number = {2},
pages = {113--125},
doi = {10.4093/jkd.2021.22.2.113}
}
EUVIMED